Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Endocrine Pathology
Erschienen in:

18.08.2016

Medullary Thyroid Carcinoma: Recent Advances Including MicroRNA Expression

verfasst von: Ying-Hsia Chu, Ricardo V. Lloyd

Erschienen in: Endocrine Pathology | Ausgabe 4/2016

Einloggen, um Zugang zu erhalten

Abstract

Medullary thyroid carcinoma (MTC) is an uncommon neuroendocrine tumor arising from the C cells in the thyroid and accounts for about 5 % of all thyroid cancers. MTC exhibits more aggressive behavior than follicular tumors, with the majority of cases presenting with lymph node metastasis. It is particularly common among patients carrying germline RET mutations with almost 100 % penetrance. Because activating RET mutations occur in over 90 % of hereditary and 40 % of sporadic MTC, clinical trials of several RET-targeting multikinase inhibitors (MKIs) have resulted in FDA approval of vandetanib and cabozantinib for the treatment of MTC. Nevertheless, in light of significant individual differences in tumor behavior and treatment responses, there has been a persistent need for research efforts to decipher the molecular events within RET-driven or non-RET-driven tumors. Recently, the gene regulatory roles of microRNAs (miRNAs) in MTC have been studied extensively. Multiple miRNA deregulations have been discovered in MTC with potential prognostic and therapeutic implications. This review provides an overview of the basic pathology of MTC and an update on recent investigational progress.
Literatur
1.
Pueblitz S, Weinberg AG, Albores-Saavedra J (1993) Thyroid C cells in the DiGeorge anomaly: a quantitative study. Pediatr Pathol 13 (4):463–473PubMedCrossRef
2.
Johansson E, Andersson L, Ornros J, Carlsson T, Ingeson-Carlsson C, Liang S, Dahlberg J, Jansson S, Parrillo L, Zoppoli P, Barila GO, Altschuler DL, Padula D, Lickert H, Fagman H, Nilsson M (2015) Revising the embryonic origin of thyroid C cells in mice and humans. Development 142 (20):3519–3528. doi:10.​1242/​dev.​126581 PubMedPubMedCentralCrossRef
3.
4.
Tang Y, Shu G, Yuan X, Jing N, Song J (2011) FOXA2 functions as a suppressor of tumor metastasis by inhibition of epithelial-to-mesenchymal transition in human lung cancers. Cell Res 21 (2):316–326. doi:10.​1038/​cr.​2010.​126 PubMedCrossRef
5.
6.
Tomita T, Millard DM (1992) C-cell hyperplasia in secondary hyperparathyroidism. Histopathology 21 (5):469–474PubMedCrossRef
7.
LiVolsi VA, Feind CR, LoGerfo P, Tashjian AH, Jr. (1973) Demonstration by immunoperoxidase staining of hyperplasia of parafollicular cells in the thyroid gland in hyperparathyroidism. J Clin Endocrinol Metab 37 (4):550–559. doi:10.​1210/​jcem-37-4-550 PubMedCrossRef
8.
Guyetant S, Wion-Barbot N, Rousselet MC, Franc B, Bigorgne JC, Saint-Andre JP (1994) C-cell hyperplasia associated with chronic lymphocytic thyroiditis: a retrospective quantitative study of 112 cases. Hum Pathol 25 (5):514–521PubMedCrossRef
9.
Biddinger PW, Brennan MF, Rosen PP (1991) Symptomatic C-cell hyperplasia associated with chronic lymphocytic thyroiditis. Am J Surg Pathol 15 (6):599–604PubMedCrossRef
10.
11.
Clark OH, Rehfeld SJ, Castner B, Stroop J, Loken HF, Deftos LJ (1978) Iodine deficiency produces hypercalcemia and hypercalcitonemia in rats. Surgery 83 (6):626–632PubMed
12.
Scopsi L, Di Palma S, Ferrari C, Holst JJ, Rehfeld JF, Rilke F (1991) C-cell hyperplasia accompanying thyroid diseases other than medullary carcinoma: an immunocytochemical study by means of antibodies to calcitonin and somatostatin. Mod Pathol 4 (3):297–304PubMed
13.
Baschieri L, Castagna M, Fierabracci A, Antonelli A, Del Guerra P, Squartini F (1989) Distribution of calcitonin- and somatostatin-containing cells in thyroid lymphoma and in Hashimoto’s thyroiditis. Appl Pathol 7 (2):99–104PubMed
14.
Machens A, Holzhausen HJ, Thanh PN, Dralle H (2003) Malignant progression from C-cell hyperplasia to medullary thyroid carcinoma in 167 carriers of RET germline mutations. Surgery 134 (3):425–431PubMedCrossRef
15.
16.
17.
18.
19.
20.
21.
Nieuwenhuijzen Kruseman AC, Bosman FT, van Bergen Henegouw JC, Cramer-Knijnenburg G, Brutel de la Riviere G (1982) Medullary differentiation of anaplastic thyroid carcinoma. Am J Clin Pathol 77 (5):541–547PubMedCrossRef
22.
Lloyd RV, Sisson JC, Marangos PJ (1983) Calcitonin, carcinoembryonic antigen and neuron-specific enolase in medullary thyroid carcinoma. Cancer 51 (12):2234–2239PubMedCrossRef
23.
Schroder S, Bocker W, Baisch H, Burk CG, Arps H, Meiners I, Kastendieck H, Heitz PU, Kloppel G (1988) Prognostic factors in medullary thyroid carcinomas. Survival in relation to age, sex, stage, histology, immunocytochemistry, and DNA content. Cancer 61 (4):806–816PubMedCrossRef
24.
Uribe M, Fenoglio-Preiser CM, Grimes M, Feind C (1985) Medullary carcinoma of the thyroid gland. Clinical, pathological, and immunohistochemical features with review of the literature. Am J Surg Pathol 9 (8):577–594PubMedCrossRef
25.
Takami H, Bessho T, Kameya T, Mimura T, Ito K, Abe O, Hosoda Y, Shikata J (1988) Immunohistochemical study of medullary thyroid carcinoma: relationship of clinical features to prognostic factors in 36 patients. World J Surg 12 (4):572–579PubMedCrossRef
26.
Sikri KL, Varndell IM, Hamid QA, Wilson BS, Kameya T, Ponder BA, Lloyd RV, Bloom SR, Polak JM (1985) Medullary carcinoma of the thyroid. An immunocytochemical and histochemical study of 25 cases using eight separate markers. Cancer 56 (10):2481–2491PubMedCrossRef
27.
Wiedenmann B, Franke WW, Kuhn C, Moll R, Gould VE (1986) Synaptophysin: a marker protein for neuroendocrine cells and neoplasms. Proc Natl Acad Sci U S A 83 (10):3500–3504PubMedPubMedCentralCrossRef
28.
Vyberg M, Horn T, Francis D, Askaa J (1990) Immunohistochemical identification of neuron-specific enolase, synaptophysin, chromogranin and endocrine granule constituent in neuroendocrine tumours. Acta Histochem Suppl 38:179–181PubMed
29.
Satoh F, Umemura S, Yasuda M, Osamura RY (2001) Neuroendocrine marker expression in thyroid epithelial tumors. Endocr Pathol 12 (3):291–299PubMedCrossRef
30.
Holm R, Sobrinho-Simoes M, Nesland JM, Gould VE, Johannessen JV (1985) Medullary carcinoma of the thyroid gland: an immunocytochemical study. Ultrastruct Pathol 8 (1):25–41PubMedCrossRef
31.
Krisch K, Krisch I, Horvat G, Neuhold N, Ulrich W (1985) The value of immunohistochemistry in medullary thyroid carcinoma: a systematic study of 30 cases. Histopathology 9 (10):1077–1089PubMedCrossRef
32.
Katoh R, Miyagi E, Nakamura N, Li X, Suzuki K, Kakudo K, Kobayashi M, Kawaoi A (2000) Expression of thyroid transcription factor-1 (TTF-1) in human C cells and medullary thyroid carcinomas. Hum Pathol 31 (3):386–393PubMedCrossRef
33.
Steiner F, Hauser-Kronberger C, Rendl G, Rodrigues M, Pirich C (2016) Expression of tenascin C, EGFR, E-cadherin, and TTF-1 in medullary thyroid carcinoma and the correlation with RET mutation status. Int J Mol Sci 17 (7). doi:10.​3390/​ijms17071093
34.
Erickson LA, Vrana JA, Theis J, Rivera M, Lloyd RV, McPhail E, Zhang J (2015) Analysis of amyloid in medullary thyroid carcinoma by mass spectrometry-based proteomic analysis. Endocr Pathol 26 (4):291–295. doi:10.​1007/​s12022-015-9390-7 PubMedCrossRef
35.
Eusebi V, Damiani S, Riva C, Lloyd RV, Capella C (1990) Calcitonin free oat-cell carcinoma of the thyroid gland. Virchows Arch A Pathol Anat Histopathol 417 (3):267–271PubMedCrossRef
36.
37.
Mendelsohn G, Wells SA, Jr., Baylin SB (1984) Relationship of tissue carcinoembryonic antigen and calcitonin to tumor virulence in medullary thyroid carcinoma. An immunohistochemical study in early, localized, and virulent disseminated stages of disease. Cancer 54 (4):657–662PubMedCrossRef
38.
39.
Saad MF, Ordonez NG, Rashid RK, Guido JJ, Hill CS, Jr., Hickey RC, Samaan NA (1984) Medullary carcinoma of the thyroid. A study of the clinical features and prognostic factors in 161 patients. Medicine (Baltimore) 63 (6):319–342CrossRef
40.
Carney JA, Sizemore GW, Hayles AV (1979) C-cell disease of the thyroid gland in multiple endocrine neoplasia, type 2b. Cancer 44 (6):2173–2183PubMedCrossRef
41.
Scopsi L, Sampietro G, Boracchi P, Del Bo R, Gullo M, Placucci M, Pilotti S (1996) Multivariate analysis of prognostic factors in sporadic medullary carcinoma of the thyroid. A retrospective study of 109 consecutive patients. Cancer 78 (10):2173–2183PubMedCrossRef
42.
43.
Farndon JR, Leight GS, Dilley WG, Baylin SB, Smallridge RC, Harrison TS, Wells SA, Jr. (1986) Familial medullary thyroid carcinoma without associated endocrinopathies: a distinct clinical entity. Br J Surg 73 (4):278–281PubMedCrossRef
44.
Feldman GL, Edmonds MW, Ainsworth PJ, Schuffenecker I, Lenoir GM, Saxe AW, Talpos GB, Roberson J, Petrucelli N, Jackson CE (2000) Variable expressivity of familial medullary thyroid carcinoma (FMTC) due to a RET V804M (GTG-->ATG) mutation. Surgery 128 (1):93–98. doi:10.​1067/​msy.​2000.​107103 PubMedCrossRef
45.
Raue F, Kotzerke J, Reinwein D, Schroder S, Roher HD, Deckart H, Hofer R, Ritter M, Seif F, Buhr H, et al. (1993) Prognostic factors in medullary thyroid carcinoma: evaluation of 741 patients from the German Medullary Thyroid Carcinoma Register. Clin Investig 71 (1):7–12PubMedCrossRef
46.
Lai AZ, Gujral TS, Mulligan LM (2007) RET signaling in endocrine tumors: delving deeper into molecular mechanisms. Endocr Pathol 18 (2):57–67PubMedCrossRef
47.
48.
Eng C, Clayton D, Schuffenecker I, Lenoir G, Cote G, Gagel RF, van Amstel HK, Lips CJ, Nishisho I, Takai SI, Marsh DJ, Robinson BG, Frank-Raue K, Raue F, Xue F, Noll WW, Romei C, Pacini F, Fink M, Niederle B, Zedenius J, Nordenskjold M, Komminoth P, Hendy GN, Mulligan LM, et al. (1996) The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA 276 (19):1575–1579PubMedCrossRef
49.
Frank-Raue K, Hoppner W, Frilling A, Kotzerke J, Dralle H, Haase R, Mann K, Seif F, Kirchner R, Rendl J, Deckart HF, Ritter MM, Hampel R, Klempa J, Scholz GH, Raue F (1996) Mutations of the ret protooncogene in German multiple endocrine neoplasia families: relation between genotype and phenotype. German Medullary Thyroid Carcinoma Study Group. J Clin Endocrinol Metab 81 (5):1780–1783. doi:10.​1210/​jcem.​81.​5.​8626834 PubMed
50.
Romei C, Mariotti S, Fugazzola L, Taccaliti A, Pacini F, Opocher G, Mian C, Castellano M, degli Uberti E, Ceccherini I, Cremonini N, Seregni E, Orlandi F, Ferolla P, Puxeddu E, Giorgino F, Colao A, Loli P, Bondi F, Cosci B, Bottici V, Cappai A, Pinna G, Persani L, Verga U, Boscaro M, Castagna MG, Cappelli C, Zatelli MC, Faggiano A, Francia G, Brandi ML, Falchetti A, Pinchera A, Elisei R, Ita MENn (2010) Multiple endocrine neoplasia type 2 syndromes (MEN 2): results from the ItaMEN network analysis on the prevalence of different genotypes and phenotypes. Eur J Endocrinol 163 (2):301–308. doi:10.​1530/​EJE-10-0333
51.
Forbes SA, Beare D, Gunasekaran P, Leung K, Bindal N, Boutselakis H, Ding M, Bamford S, Cole C, Ward S, Kok CY, Jia M, De T, Teague JW, Stratton MR, McDermott U, Campbell PJ (2015) COSMIC: exploring the world’s knowledge of somatic mutations in human cancer. Nucleic Acids Res 43 (Database issue):D805–D811. doi:10.​1093/​nar/​gku1075 PubMedCrossRef
52.
Santoro M, Carlomagno F, Romano A, Bottaro DP, Dathan NA, Grieco M, Fusco A, Vecchio G, Matoskova B, Kraus MH, et al. (1995) Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B. Science 267 (5196):381–383PubMedCrossRef
53.
Freche B, Guillaumot P, Charmetant J, Pelletier L, Luquain C, Christiansen D, Billaud M, Manie SN (2005) Inducible dimerization of RET reveals a specific AKT deregulation in oncogenic signaling. J Biol Chem 280 (44):36584–36591. doi:10.​1074/​jbc.​M505707200 PubMedCrossRef
54.
55.
Leboulleux S, Travagli JP, Caillou B, Laplanche A, Bidart JM, Schlumberger M, Baudin E (2002) Medullary thyroid carcinoma as part of a multiple endocrine neoplasia type 2B syndrome: influence of the stage on the clinical course. Cancer 94 (1):44–50PubMedCrossRef
56.
Jasim S, Ying AK, Waguespack SG, Rich TA, Grubbs EG, Jimenez C, Hu MI, Cote G, Habra MA (2011) Multiple endocrine neoplasia type 2B with a RET proto-oncogene A883F mutation displays a more indolent form of medullary thyroid carcinoma compared with a RET M918T mutation. Thyroid 21 (2):189–192. doi:10.​1089/​thy.​2010.​0328 PubMedPubMedCentralCrossRef
57.
Plaza Menacho I, Koster R, van der Sloot AM, Quax WJ, Osinga J, van der Sluis T, Hollema H, Burzynski GM, Gimm O, Buys CH, Eggen BJ, Hofstra RM (2005) RET-familial medullary thyroid carcinoma mutants Y791F and S891A activate a Src/JAK/STAT3 pathway, independent of glial cell line-derived neurotrophic factor. Cancer Res 65 (5):1729–1737. doi:10.​1158/​0008-5472.​CAN-04-2363 PubMedCrossRef
58.
Engelmann D, Koczan D, Ricken P, Rimpler U, Pahnke J, Li Z, Putzer BM (2009) Transcriptome analysis in mouse tumors induced by Ret-MEN2/FMTC mutations reveals subtype-specific role in survival and interference with immune surveillance. Endocr Relat Cancer 16 (1):211–224. doi:10.​1677/​ERC-08-0158 PubMedCrossRef
59.
Mise N, Drosten M, Racek T, Tannapfel A, Putzer BM (2006) Evaluation of potential mechanisms underlying genotype-phenotype correlations in multiple endocrine neoplasia type 2. Oncogene 25 (50):6637–6647. doi:10.​1038/​sj.​onc.​1209669 PubMedCrossRef
60.
Baylin SB, Hsu SH, Gann DS, Smallridge RC, Wells SA, Jr. (1978) Inherited medullary thyroid carcinoma: a final monoclonal mutation in one of multiple clones of susceptible cells. Science 199 (4327):429–431PubMedCrossRef
61.
Ye L, Santarpia L, Cote GJ, El-Naggar AK, Gagel RF (2008) High resolution array-comparative genomic hybridization profiling reveals deoxyribonucleic acid copy number alterations associated with medullary thyroid carcinoma. J Clin Endocrinol Metab 93 (11):4367–4372. doi:10.​1210/​jc.​2008-0912 PubMedPubMedCentralCrossRef
62.
Heilmann AM, Subbiah V, Wang K, Sun JX, Elvin JA, Chmielecki J, Sherman SI, Murthy R, Busaidy NL, Subbiah I, Yelensky R, Nangia C, Vergilio JA, Khan SA, Erlich RL, Lipson D, Ross JS, Miller VA, Shah MH, Ali SM, Stephens PJ (2016) Comprehensive genomic profiling of clinically advanced medullary thyroid carcinoma. Oncology 90 (6):339–346. doi:10.​1159/​000445978 PubMedCrossRef
63.
Capp C, Wajner SM, Siqueira DR, Brasil BA, Meurer L, Maia AL (2010) Increased expression of vascular endothelial growth factor and its receptors, VEGFR-1 and VEGFR-2, in medullary thyroid carcinoma. Thyroid 20 (8):863–871. doi:10.​1089/​thy.​2009.​0417 PubMedCrossRef
64.
Rodriguez-Antona C, Pallares J, Montero-Conde C, Inglada-Perez L, Castelblanco E, Landa I, Leskela S, Leandro-Garcia LJ, Lopez-Jimenez E, Leton R, Cascon A, Lerma E, Martin MC, Carralero MC, Mauricio D, Cigudosa JC, Matias-Guiu X, Robledo M (2010) Overexpression and activation of EGFR and VEGFR2 in medullary thyroid carcinomas is related to metastasis. Endocr Relat Cancer 17 (1):7–16. doi:10.​1677/​ERC-08-0304 PubMedCrossRef
65.
Lin H, Jiang X, Zhu H, Jiang W, Dong X, Qiao H, Sun X, Jiang H (2016) 2ME2 inhibits the activated hypoxia-inducible pathways by cabozantinib and enhances its efficacy against medullary thyroid carcinoma. Tumour Biol 37 (1):381–391. doi:10.​1007/​s13277-015-3816-1 PubMedCrossRef
66.
67.
Eng C, Mulligan LM, Healey CS, Houghton C, Frilling A, Raue F, Thomas GA, Ponder BA (1996) Heterogeneous mutation of the RET proto-oncogene in subpopulations of medullary thyroid carcinoma. Cancer Res 56 (9):2167–2170PubMed
68.
69.
70.
Ciampi R, Mian C, Fugazzola L, Cosci B, Romei C, Barollo S, Cirello V, Bottici V, Marconcini G, Rosa PM, Borrello MG, Basolo F, Ugolini C, Materazzi G, Pinchera A, Elisei R (2013) Evidence of a low prevalence of RAS mutations in a large medullary thyroid cancer series. Thyroid 23 (1):50–57. doi:10.​1089/​thy.​2012.​0207 PubMedCrossRef
71.
Mancikova V, Inglada-Perez L, Curras-Freixes M, de Cubas AA, Gomez A, Leton R, Kersten I, Leandro-Garcia LJ, Comino-Mendez I, Apellaniz-Ruiz M, Sanchez L, Cascon A, Sastre-Marcos J, Garcia JF, Rodriguez-Antona C, Robledo M (2014) VEGF, VEGFR3, and PDGFRB protein expression is influenced by RAS mutations in medullary thyroid carcinoma. Thyroid 24 (8):1251–1255. doi:10.​1089/​thy.​2013.​0579 PubMedCrossRef
72.
Sherman SI, Cohen EEW, Schoffski P, Elisei R, Schlumberger M, Wirth LJ, Mangeshkar M, Aftab DT, Clary DO, Brose MS (2013) Efficacy of cabozantinib (Cabo) in medullary thyroid cancer (MTC) patients with RAS or RET mutations: Results from a phase III study. Journal of Clinical Oncology (Meeting Abstracts) 31 (Suppl):Abstr 6000
73.
Rowinsky EK, Windle JJ, Von Hoff DD (1999) Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development. J Clin Oncol 17 (11):3631–3652PubMed
74.
Hong DS, Cabanillas ME, Wheler J, Naing A, Tsimberidou AM, Ye L, Busaidy NL, Waguespack SG, Hernandez M, El Naggar AK, Bidyasar S, Wright J, Sherman SI, Kurzrock R (2011) Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies. J Clin Endocrinol Metab 96 (4):997–1005. doi:10.​1210/​jc.​2010-1899 PubMedPubMedCentralCrossRef
75.
Ahmed M, Barbachano Y, Riddell A, Hickey J, Newbold KL, Viros A, Harrington KJ, Marais R, Nutting CM (2011) Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: a phase II study in a UK based population. Eur J Endocrinol 165 (2):315–322. doi:10.​1530/​EJE-11-0129 PubMedCrossRef
76.
Santarpia L, Calin GA, Adam L, Ye L, Fusco A, Giunti S, Thaller C, Paladini L, Zhang X, Jimenez C, Trimarchi F, El-Naggar AK, Gagel RF (2013) A miRNA signature associated with human metastatic medullary thyroid carcinoma. Endocr Relat Cancer 20 (6):809–823. doi:10.​1530/​ERC-13-0357 PubMedCrossRef
77.
Abraham D, Jackson N, Gundara JS, Zhao J, Gill AJ, Delbridge L, Robinson BG, Sidhu SB (2011) MicroRNA profiling of sporadic and hereditary medullary thyroid cancer identifies predictors of nodal metastasis, prognosis, and potential therapeutic targets. Clin Cancer Res 17 (14):4772–4781. doi:10.​1158/​1078-0432.​CCR-11-0242 PubMedCrossRef
78.
Mian C, Pennelli G, Fassan M, Balistreri M, Barollo S, Cavedon E, Galuppini F, Pizzi M, Vianello F, Pelizzo MR, Girelli ME, Rugge M, Opocher G (2012) MicroRNA profiles in familial and sporadic medullary thyroid carcinoma: preliminary relationships with RET status and outcome. Thyroid 22 (9):890–896. doi:10.​1089/​thy.​2012.​0045 PubMedPubMedCentralCrossRef
79.
80.
81.
Puppin C, Durante C, Sponziello M, Verrienti A, Pecce V, Lavarone E, Baldan F, Campese AF, Boichard A, Lacroix L, Russo D, Filetti S, Damante G (2014) Overexpression of genes involved in miRNA biogenesis in medullary thyroid carcinomas with RET mutation. Endocrine 47 (2):528–536. doi:10.​1007/​s12020-014-0204-3 PubMedCrossRef
82.
83.
Modigliani E, Cohen R, Campos JM, Conte-Devolx B, Maes B, Boneu A, Schlumberger M, Bigorgne JC, Dumontier P, Leclerc L, Corcuff B, Guilhem I (1998) Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. The GETC Study Group. Groupe d’etude des tumeurs a calcitonine. Clin Endocrinol (Oxf) 48 (3):265–273CrossRef
84.
Chong GC, Beahrs OH, Sizemore GW, Woolner LH (1975) Medullary carcinoma of the thyroid gland. Cancer 35 (3):695–704PubMedCrossRef
85.
Pelizzo MR, Boschin IM, Bernante P, Toniato A, Piotto A, Pagetta C, Nibale O, Rampin L, Muzzio PC, Rubello D (2007) Natural history, diagnosis, treatment and outcome of medullary thyroid cancer: 37 years experience on 157 patients. Eur J Surg Oncol 33 (4):493–497. doi:10.​1016/​j.​ejso.​2006.​10.​021 PubMedCrossRef
86.
Deutschbein T, Matuszczyk A, Moeller LC, Unger N, Yuece A, Lahner H, Mann K, Petersenn S (2011) Treatment of advanced medullary thyroid carcinoma with a combination of cyclophosphamide, vincristine, and dacarbazine: a single-center experience. Exp Clin Endocrinol Diabetes 119 (9):540–543. doi:10.​1055/​s-0031-1279704 PubMedCrossRef
87.
Wu LT, Averbuch SD, Ball DW, de Bustros A, Baylin SB, McGuire WP, 3rd (1994) Treatment of advanced medullary thyroid carcinoma with a combination of cyclophosphamide, vincristine, and dacarbazine. Cancer 73 (2):432–436PubMedCrossRef
88.
Nocera M, Baudin E, Pellegriti G, Cailleux AF, Mechelany-Corone C, Schlumberger M (2000) Treatment of advanced medullary thyroid cancer with an alternating combination of doxorubicin-streptozocin and 5 FU-dacarbazine. Groupe d’Etude des Tumeurs a Calcitonine (GETC). Br J Cancer 83 (6):715–718. doi:10.​1054/​bjoc.​2000.​1314 PubMedPubMedCentralCrossRef
89.
Shimaoka K, Schoenfeld DA, DeWys WD, Creech RH, DeConti R (1985) A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer 56 (9):2155–2160PubMedCrossRef
90.
Wells, SA Jr., Asa SL, Dralle H, Elisei R, Evans DB, Gagel RF, Lee N, Machens A, Moley JF, Pacini F, Raue F, Frank-Raue K, Robinson B, Rosenthal MS, Santoro M, Schlumberger M, Shah M, Waguespack SG, American Thyroid Association Guidelines Task Force on Medullary Thyroid C (2015) Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid 25 (6):567–610. doi:10.​1089/​thy.​2014.​0335 PubMedPubMedCentralCrossRef
91.
92.
93.
Kurzrock R, Sherman SI, Ball DW, Forastiere AA, Cohen RB, Mehra R, Pfister DG, Cohen EE, Janisch L, Nauling F, Hong DS, Ng CS, Ye L, Gagel RF, Frye J, Muller T, Ratain MJ, Salgia R (2011) Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol 29 (19):2660–2666. doi:10.​1200/​JCO.​2010.​32.​4145 PubMedPubMedCentralCrossRef
94.
Lam ET, Ringel MD, Kloos RT, Prior TW, Knopp MV, Liang J, Sammet S, Hall NC, Wakely PE, Jr., Vasko VV, Saji M, Snyder PJ, Wei L, Arbogast D, Collamore M, Wright JJ, Moley JF, Villalona-Calero MA, Shah MH (2010) Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. J Clin Oncol 28 (14):2323–2330. doi:10.​1200/​JCO.​2009.​25.​0068 PubMedPubMedCentralCrossRef
95.
Cohen EE, Rosen LS, Vokes EE, Kies MS, Forastiere AA, Worden FP, Kane MA, Sherman E, Kim S, Bycott P, Tortorici M, Shalinsky DR, Liau KF, Cohen RB (2008) Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol 26 (29):4708–4713. doi:10.​1200/​JCO.​2007.​15.​9566 PubMedPubMedCentralCrossRef
96.
Locati LD, Licitra L, Agate L, Ou SH, Boucher A, Jarzab B, Qin S, Kane MA, Wirth LJ, Chen C, Kim S, Ingrosso A, Pithavala YK, Bycott P, Cohen EE (2014) Treatment of advanced thyroid cancer with axitinib: phase 2 study with pharmacokinetic/pharmacodynamic and quality-of-life assessments. Cancer 120 (17):2694–2703. doi:10.​1002/​cncr.​28766 PubMedCrossRef
97.
Cohen EE, Needles BM, Cullen KJ, Wong SJ, Wade III JL, Ivy SP, Villaflor VM, Seiwert TY, Nichols K, Vokes EE (2008) Phase 2 study of sunitinib in refractory thyroid cancer. Journal of Clinical Oncology (Meeting Abstracts) 26 (15S):6025
98.
De Souza JA, Busaidy N, Zimrin A, Seiwert TY, Villaflor VM, Poluru KB, Reddy PL, Nam J, Vokes EE, Cohen EE (2010) Phase II trial of sunitinib in medullary thyroid cancer (MTC). Journal of Clinical Oncology (Meeting Abstracts) 28 (15S):5504
99.
Carr LL, Mankoff DA, Goulart BH, Eaton KD, Capell PT, Kell EM, Bauman JE, Martins RG (2010) Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clin Cancer Res 16 (21):5260–5268. doi:10.​1158/​1078-0432.​CCR-10-0994 PubMedPubMedCentralCrossRef
100.
Schneider TC, de Wit D, Links TP, van Erp NP, van der Hoeven JJ, Gelderblom H, van Wezel T, van Eijk R, Morreau H, Guchelaar HJ, Kapiteijn E (2015) Beneficial effects of the mTOR inhibitor everolimus in patients with advanced medullary thyroid carcinoma: subgroup results of a phase ii trial. Int J Endocrinol 2015:348124. doi:10.​1155/​2015/​348124 PubMedPubMedCentralCrossRef
101.
Schlumberger M, Jarzab B, Cabanillas ME, Robinson B, Pacini F, Ball DW, McCaffrey J, Newbold K, Allison R, Martins RG, Licitra LF, Shah MH, Bodenner D, Elisei R, Burmeister L, Funahashi Y, Ren M, O’Brien JP, Sherman SI (2016) A phase II trial of the multitargeted tyrosine kinase inhibitor lenvatinib (E7080) in advanced medullary thyroid cancer. Clin Cancer Res 22 (1):44–53. doi:10.​1158/​1078-0432.​CCR-15-1127 PubMedCrossRef
102.
Bible KC, Suman VJ, Molina JR, Smallridge RC, Maples WJ, Menefee ME, Rubin J, Karlin N, Sideras K, Morris JC III, McIver B, Hay I, Fatourechi V, Burton JK, Webster KP, Bieber C, Traynor AM, Flynn PJ, Cher Goh B, Isham CR, Harris P, Erlichman C, Endocrine Malignancies Disease Oriented Group MCCC, the Mayo Phase C (2014) A multicenter phase 2 trial of pazopanib in metastatic and progressive medullary thyroid carcinoma: MC057H. J Clin Endocrinol Metab 99 (5):1687–1693. doi:10.​1210/​jc.​2013-3713 PubMedPubMedCentralCrossRef
103.
de Groot JW, Zonnenberg BA, van Ufford-Mannesse PQ, de Vries MM, Links TP, Lips CJ, Voest EE (2007) A phase II trial of imatinib therapy for metastatic medullary thyroid carcinoma. J Clin Endocrinol Metab 92 (9):3466–3469. doi:10.​1210/​jc.​2007-0649 PubMedCrossRef
104.
Wells SA, Jr., Robinson BG, Gagel RF, Dralle H, Fagin JA, Santoro M, Baudin E, Elisei R, Jarzab B, Vasselli JR, Read J, Langmuir P, Ryan AJ, Schlumberger MJ (2012) Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol 30 (2):134–141. doi:10.​1200/​JCO.​2011.​35.​5040 PubMedCrossRef
105.
Elisei R, Schlumberger MJ, Muller SP, Schoffski P, Brose MS, Shah MH, Licitra L, Jarzab B, Medvedev V, Kreissl MC, Niederle B, Cohen EE, Wirth LJ, Ali H, Hessel C, Yaron Y, Ball D, Nelkin B, Sherman SI (2013) Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol 31 (29):3639–3646. doi:10.​1200/​JCO.​2012.​48.​4659 PubMedPubMedCentralCrossRef
106.
Carlomagno F, Guida T, Anaganti S, Vecchio G, Fusco A, Ryan AJ, Billaud M, Santoro M (2004) Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors. Oncogene 23 (36):6056–6063. doi:10.​1038/​sj.​onc.​1207810 PubMedCrossRef
107.
108.
Metadaten
Titel
Medullary Thyroid Carcinoma: Recent Advances Including MicroRNA Expression
verfasst von
Ying-Hsia Chu
Ricardo V. Lloyd
Publikationsdatum
18.08.2016
Verlag
Springer US
Erschienen in
Endocrine Pathology / Ausgabe 4/2016
Print ISSN: 1046-3976
Elektronische ISSN: 1559-0097
DOI
https://doi.org/10.1007/s12022-016-9449-0

Weitere Artikel der Ausgabe 4/2016

Detection of Molecular Alterations in Medullary Thyroid Carcinoma Using Next-Generation Sequencing: an Institutional Experience

Hürthle Cells Adenoma of the Thyroid with Post-surgical Implants in the Neck: Clinical, Morphological, and Molecular Analysis of Three Cases

Stage-Specific Embryonic Antigen-1 (SSEA-1) Expression in Thyroid Tissues

A Calcitonin Non-producing Neuroendocrine Tumor of the Thyroid Gland

Detailed Lymph Node Sectioning of Papillary Thyroid Carcinoma Specimen Increases the Number of pN1a Patients

Mixed Neuroendocrine-Nonneuroendocrine Neoplasms (MiNENs): Unifying the Concept of a Heterogeneous Group of Neoplasms

Neu im Fachgebiet Pathologie

Identifizierung von verschiedenen Körperflüssigkeiten anhand epigenetischer Methoden

Straftaten, insbesondere gegen die sexuelle Selbstbestimmung, finden häufig innerhalb des bekannten oder familiären Umfelds statt, sodass beteiligte Personen berechtigte Spurenleger sind. Der Nachweis einer Person als Verursacher von …

Assistierte Suizide in München: angewendete Arzneistoffe und dokumentierte Komplikationen

  • Originalien

Erste Daten zur Klientel, zur Rolle von Sterbehilfeorganisationen und zu beteiligten Ärzten sowie zur Qualität vorliegender Gutachten bei assistierten Suiziden (AS) wurden kürzlich in dieser Zeitschrift veröffentlicht [ 1 – 3 ]. Das oral …

Beinahetreffer bei DNA-Untersuchungen nach § 81e Strafprozessordnung (StPO)

Bis 23.08.2017 erlaubte § 81e Abs. 1 S. 1 StPO DNA-Untersuchungen nur, „soweit sie zur Feststellung der Abstammung oder der Tatsache, ob aufgefundenes Spurenmaterial von dem Beschuldigten oder dem Verletzten stammt, erforderlich sind; hierbei darf …

SARIFA – ein neuer entitätenübergreifender Biomarker

  • Übersicht

SARIFA (Akronym für „Stroma Areactive Invasion Front Areas“) ist ein neuer prognostischer Biomarker in Karzinomen. Im Wesentlich beschreibt SARIFA das Auftreten eines direkten Kontakts von mindestens 5 Tumorzellen mit ortsständigen Fettzellen.